PATENT CLAIM ANALYSIS

Application Number: 16066921
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-01
Patent Classification: ["514", "365000"]

Abstract:
The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.

Claim (Index 15):
The pharmaceutical composition of any one of  claims 1 - 14 , wherein said pharmaceutical composition comprises a calcium channel inhibitor.

Metadata:
- Claim Count in Document: 115.0
- Percentile: 98.0
- Lexical Diversity: 1.41667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14987586', '15231549', '15729046', '10069744', '13486502']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8086442697218825
- 35 USC 102 Novelty (BERT): 0.540124285034712
- Combined Prediction Score: 0.7817922712531655
- Mean Citation Score: 351.3474
- Max Citation Score: 392.481
- Similarity Product: 244.23204800140857

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test